Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma.

Zhao, Yang; Lai, JiaYing; Liang, RunBin; He, MinKe; Shi, Ming

Zhao, Yang; Lai, JiaYing; Liang, RunBin; He, MinKe; Shi, Ming.

Afiliación

Zhao Y; Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Lai J; HuiDong Senior Middle School, Huidong, Huizhou, China.
Liang R; Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
He M; Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Shi M; Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

J Interv Med ; 2(2): 78-83, 2019 May.

Article en En | MEDLINE | ID: mdl-34805877

Palabras clave

Barcelona clinic liver cancer stage C; Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Oxaliplatin; Sorafenib

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Interv Med Año: 2019 Tipo del documento: Article País de afiliación: China Pais de publicación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google